Cixutumumab

Metastatic Breast Cancer

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Dormant

B

63/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 57/ 100
Competitive Position: 73/ 100

Competitive context

891 Active assets in the Metastatic Breast Cancer cohort.

Asset / Sponsor	Phase	Rating
Lapatinib University of New Mexico	Phase 3	BBB
Darolutamide Vandana Abramson	Phase 2	BBB
Trastuzumab Duocarmazine Byondis B.V.	Phase 3	BB
ERIBULIN MONOMETHANESULFONATE Henan Cancer Hospital	Phase 4	BB
Palbociclib Hoffmann-La Roche	Phase 4	BB

View all 50 →

Same molecule, other indications

Cixutumumab is also rated in:

non-small cell lung carcinomaDormant

BB

Indicative ·

71 / 100

Stage IV Breast Cancer AJCC v6 and v7Dormant

BB

Indicative ·

71 / 100

Ewing sarcoma/peripheral primitive neuroectodermal tumorDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.